Navigation Links
Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
Date:4/6/2009

Company to Submit a Supplemental New Drug Application to Expand the NUVIGIL(R) Label

FRAZER, Pa., April 6 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a phase three clinical trial of NUVIGIL(R) (armodafinil) Tablets [C-IV] as a treatment for excessive sleepiness associated with jet lag disorder. Based on these findings, Cephalon(R) will file a supplemental New Drug Application with the U.S. Food and Drug Administration to expand the indications for NUVIGIL during the third quarter of this year.

The efficacy and safety of NUVIGIL as a potential treatment for acute excessive sleepiness associated with jet lag disorder were evaluated over the course of three days in a randomized, double-blind, placebo-controlled study of 427 healthy adults who had experienced jet lag symptoms during the previous five years. Participants in the study traveled eastbound from the United States to France where they were then examined at a sleep facility. Clinical efficacy was evaluated using two primary endpoints: an objective assessment -- the Multiple Sleep Latency Test (MSLT), and a subjective assessment -- the Patient Global Impression of Severity (PGI-S). Patients taking NUVIGIL (150 mg) showed a statistically significant improvement over placebo as measured by the MSLT [p<0.0001] and the PGI-S [p<0.05]. The results of this study will be submitted for presentation at a future medical meeting.

"After flying the subjects over the Atlantic, we objectively evaluated those receiving placebo versus those receiving NUVIGIL," said Dr. Lesley Russell, Chief Medical Officer and Executive Vice President at Cephalon. "We discovered that those on placebo were as excessivel
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
2. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
3. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
4. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
5. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
8. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
9. Schering-Plough Announces Results of the Early ACS Trial
10. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
11. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  With a vision ... health medications, a Global Pharmaceutical and Biotech manufacturer ... technology and turnkey solution to protect their animal ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... was serialized and aggregated by the Xyntek and ...
(Date:10/22/2014)... 2014   BioNano Genomics , the genome ... centers to purchase an Irys™ System . Among ... Institute (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope ... a comprehensive view of a genome was a ... not deliver the scalability or reliability to detect ...
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... and local dignitaries ushered in a new chapter in ... of a laboratory complex designed to speed up cures ... housing 78 labs and other facilities, signifies a break ... different fields and allowing them to communicate more effectively. ...
... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN ... a new study examining the immunogenicity and safety profiles of ... and younger adults to a standard dose of Fluzone vaccine. ... the Infectious Diseases Society of America on October 21, 2011. ...
Cached Medicine Technology:MUSC Dedicates New Bioengineering and Drug Discovery Hubs 2Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 2Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 3Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 4Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 5Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 6
(Date:10/22/2014)... 2014 (HealthDay News) -- The United States is ... Ebola-affected nations of West Africa land at one ... infection with the virus. In a statement ... that 94 percent of air passengers from Guinea, ... of these five airports -- New York City,s ...
(Date:10/22/2014)... Grants Pass, OR (PRWEB) October 22, 2014 ... while Southern California’s fresh water supply runs dangerously low, ... climate change. Southern Oregon’s rivers, despite the lowest mountain ... fast even in late summer and early autumn.* That ... Urness, authors of the new book “Hiking Southern Oregon,” ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, ... Sales, will be speaking on the subject of “Event ... October 28, at the Holiday Inn in New York ... well as a Tech Demo at 12:45pm, to educate ... more engaging event experience. , The Annual Meetings Technology ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Two sisters ... and heart damage. Ilina and Medha Krishen use ... for sounds of trouble in breathing patterns or heartbeats. ... School in Michigan, wanted to find a way to ... air pollutants. Using an electronic stethoscope, Ilina recorded one ...
(Date:10/22/2014)... By Dennis Thompson HealthDay ... freelance cameraman who was diagnosed with Ebola while working for ... system and can leave the special isolation unit at Nebraska Medical ... two weeks, the hospital said Tuesday. A blood test confirmed ... Ashoka Mukpo, 33, can head home to Providence, R.I., NBC ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... The hair-like protrusions of bacteria have a sticky protein on ... of these protrusions are in the form of a coiled// ... tightly, even through rough fluid flow inside the body, researchers ... group of researchers at the University of Washington in Seattle ...
... by Karolinska Institutet in Sweden and Makerere University in Uganda ... pregnant women// and this is the reason for pregnant women ... is the worst of the four malaria parasites that infect ... the placenta of pregnant women, with fatal consequences for both ...
... HIV/AIDS in the Northeast say that the media is insensitive ... to them// . ,"I have come across ... from me, and didn't even look at my eyes during ... the stigma," said Vanlalmuana, the president of the Positive Network ...
... indirect costs, the financial burden on a woman who has ... $1 million during her lifetime// . But even a woman ... condition to take a toll in the neighborhood of $800,000, ... M.D., medical director of the Preventive and Rehabilitative Cardiac Center ...
... which provided stem cell therapy for her multiple sclerosis. She ... and her illness has not improved. ,Speaking to ... to where I was before the treatment. It's quite gutting ... to work and it didn't. I spoke to the doctor ...
... of death almost three times pronounced for women undergoing ... , ,Catherine Deneux-Tharaux, M.D., M.P.H., of Hospital ... either during or within a month after delivery, were ... a vaginal delivery; irrespective of whether the caesarian was ...
Cached Medicine News:Health News:Fimbriae Help Bacteria Stick Around Inside the Body 2Health News:Malarial Parasite Hides In Placenta 2Health News:Study Says Chest Pain Toll in Women is More than Physical 2Health News:Study Says Chest Pain Toll in Women is More than Physical 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: